This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.
[EN] SMALL MOLECULE INHIBITORS OF EGFR AND PI3K<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE L'EGFR ET DE PI3K
申请人:UNIV MICHIGAN REGENTS
公开号:WO2016100347A3
公开(公告)日:2016-08-18
SMALL MOLECULE INHIBITORS OF EGFR AND PI3K
申请人:The Regents of The University of Michigan
公开号:EP3233085A2
公开(公告)日:2017-10-25
COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER
申请人:The Regents Of The University Of Michigan
公开号:EP3955923A1
公开(公告)日:2022-02-23
[EN] COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER<br/>[FR] COMBINAISON D'INHIBITEURS DE POINTS DE CONTRÔLE POUR LE TRAITEMENT DU CANCER
申请人:UNIV MICHIGAN REGENTS
公开号:WO2020215037A1
公开(公告)日:2020-10-22
A combination comprising a compound of Formula (I) and/or Formula (Ia), or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator. Methods for the prevention and treatment of a cancer comprises administering to a subject in need thereof, a therapeutically effective amount of a combination, the combination comprising: a compound of Formula (I) and/or Formula (Ia), or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator.